US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Swiss vaccine company LimmaTech Biologics has in-licensed technology from GSK to continue development and commercialization of a quadrivalent shigellosis vaccine candidate. 20 July 2023
Boston, USA-based biotech start-up Jnana Therapeutics has appointed Dr George Vratsanos as its chief medical officer and head of research and development. 20 July 2023
Brighton, UK-based infectious disease specialist Destiny Pharma today announced that Chris Tovey will join the company as chief executive (CEO) on September 1, 2023. 19 July 2023
UK-based CAR-T therapies specialist Leucid Bio today announced the appointment of Filippo Petti as its chief executive (CEO), with immediate effect. 18 July 2023
Elmar Schnee has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics. 17 July 2023
A stronger focus on oncology, and in particular well known targets such as the HER2 and HER3 proteins, marks a change in strategy for Hillstream BioPharma. 13 July 2023
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global sector trade body, today announced a new line up for its chief executive (CEO) leadership team for the coming two years. 12 July 2023
Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease and other therapy areas, has appointed Rachael Lester as its chief business officer. 11 July 2023
Privately-held Italian drugmaker Chiesi Farmaceutici has appointed Alessandro Chiesi as chairman of the Chiesi Group. Additionally, it said that Maria Paola Chiesi becomes vice chair. 7 July 2023
Lars Petersen has been named as the new president and chief executive officer (CEO) of FUJIFILM Diosynth Biotechnologies, a Japanese contract development and manufacturing organization (CDMO), and subsidiary of FUJIFILM Corp, effective immediately. 29 June 2023
San Diego, USA-based biotech AvantGen has appointed of Jordon Wang as its new chief operating officer (COO) and senior vice president of technology development. 29 June 2023
UK cancer immunotherapy firm Immodulon has appointed Richard Couch as chief technology officer and Owen Vaughan as chief regulatory officer. 26 June 2023
Privately-held Danish dermatology specialist LEO Pharma has appointed Kreesten Meldgaard Madsen as chief development officer and, effective Tuesday, he joined LEO Pharma’s global leadership team (GLT). 21 June 2023
Adcendo, a Danish biotech focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has appointed Lone Ottesen its chief medical officer (CMO). 20 June 2023
The appointment of a new chief executive at immune-mediated disease specialist Veralox Therapeutics coincides with a fresh investment of $24 million from new and existing backers. 20 June 2023
Texas, USA-based drug developer Reata Pharmaceuticals says that the US Food and Drug Administration (FDA) accepted for filing the Prior Approval Supplement (PAS) to update the drug substance specification for Skyclarys (omaveloxolone). 16 June 2023